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more important that weight gain during pregnancy for re-
ducing the risk of obesity in the offspring. The effects of dif-
ferent polyunsaturated fatty acids on MetS and weight loss 
require clarification.  © 2014 S. Karger AG, Basel 
 Introduction 
 The metabolic syndrome (MetS) is a collection of re-
lated risk factors that increases the risk of type 2 diabetes, 
cardiovascular disease, stroke and other diseases. Indi-
viduals with MetS have a 5-fold greater risk of developing 
type 2 diabetes and are 3 times more likely to have a heart 
attack or stroke compared with those without the syn-
drome  [1] . According to the International Diabetes Fed-
eration, the worldwide prevalence of MetS is 25% and in-
creasing rapidly  [2] .
 The International Diabetes Federation published a 
worldwide definition of MetS based on central obesity de-
fined as waist circumference with ethnicity-specific val-
ues, plus any two of the following four factors: plasma 
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 Abstract 
 A symposium on the health significance of dietary fat in the 
prevention and treatment of the metabolic syndrome (MetS) 
was held at the 20th International Congress of Nutrition in 
Granada, Spain, on September 19, 2013. Four nutrition ex-
perts addressed the topics of dietary fat and obesity, effects 
of dietary fat quality in obesity and insulin resistance, influ-
ence of early nutrition on the later risk of MetS and the rela-
tive merits of high- or low-fat diets in counteracting MetS. 
Participants agreed that preventing weight gain and achiev-
ing weight loss in overweight and obese patients were key 
strategies for reducing MetS. Both low-fat and low-carbohy-
drate diets are associated with weight loss, but adherence to 
the diet is the most important factor in achieving success. 
Avoidance of high saturated fats contributes to lower health 
risks among obese, MetS and diabetic patients. Further, 
healthy maternal weight at conception and in pregnancy is 
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triglycerides  ≥ 1.7 mmol/l (150 mg/dl); high-density-li-
poprotein cholesterol <1.03 mmol/l (<40 mg/dl) in males 
or <1.29 mmol/l (<50 mg/dl) in females; blood pressure: 
systolic pressure  ≥ 130 or diastolic pressure  ≥ 85 mm Hg, 
and fasting plasma glucose  ≥ 5.6 mmol/l ( ≥ 100 mg/dl) 
 [2] . It is generally agreed that insulin resistance is the 
principal metabolic abnormality in MetS  [3, 4] and is re-
flected in the assessment of abdominal obesity, which is 
easier to measure clinically. 
 The prevalence of MetS parallels the rising rates of 
obesity  [5] , although approximately 30% of obese indi-
viduals maintain healthy cardiometabolic profiles  [6] . 
Similarly, not all those with insulin resistance are obese 
 [7] . Those with abdominal obesity have the highest risk 
of MetS and type 2 diabetes  [8] . Intervention studies have 
shown that weight loss and lifestyle intervention reduce 
the risk of progression to type 2 diabetes  [9, 10] . Improve-
ments in diet quality beyond macronutrient distribution 
are significantly associated with reductions in weight, fat 
mass and visceral adipose tissue in MetS individuals fol-
lowing an energy-restricted, lifestyle intervention pro-
gram for 1 year  [11] . Two questions arise about the role 
of dietary fat in MetS: to what extent do dietary fat and fat 
quality contribute to weight gain or loss, and what are 
their effects on the development of MetS independent of 
weight? To address these topics, the International Expert 
Movement to Improve Dietary Fat Quality  [12] , an initia-
tive of the International Union of Nutritional Sciences, 
funded by an unrestricted educational grant from Unile-
ver NV, hosted a symposium at the 20th International 
Congress of Nutrition in Granada, Spain, on September 
19, 2013. This paper summarizes that symposium.
 Dietary Fat and Obesity 
 Susan Jebb, professor of diet and population health, 
Oxford University, UK, traced the research on fat intake 
and obesity from ecological studies through controlled 
intervention trials and comparisons among popular 
weight loss programs. Her presentation addressed the 
question whether reducing total fat intake is crucial in 
weight loss or whether total energy intake matters more. 
Although cross-cultural studies demonstrated a linear re-
lationship between dietary percent energy (%E) from fat 
and percent of overweight individuals in the population 
 [13] , studies among more homogeneous populations 
found no association  [14] . Yet the efficient absorption of 
fat and its relative resistance to oxidation, compared with 
carbohydrates, suggest that high-fat diets could be par-
ticularly liable to lead to weight gain. Experimental stud-
ies have also suggested that high-fat foods are only weak-
ly satiating relative to other macronutrients and may con-
tribute to passive overconsumption and excess energy 
intake  [15, 16] .
 Detailed studies on macronutrient balance in humans 
during overfeeding, conducted within whole-body calo-
rimeters, showed that while carbohydrate was readily ox-
idized, fat oxidation decreased as overfeeding continued, 
leading to fat accumulation  [17] . During periods of un-
derfeeding, fat oxidation remained high and unrelated to 
fat intake. Studies of men confined to a whole-body calo-
rimeter showed that as the energy density of the diet in-
creased (covert manipulations), ad libitum energy con-
sumption also increased  [18] . However, when the energy 
density of diets was held constant and the %E from fat 
increased from 20 to 60%, total energy intake remained 
constant ( fig.  1 )  [19] . Other experimental studies have 
consistently demonstrated that energy intake increases 
with increasing energy density  [16] .
 However, longer-term trials involving fat manipula-
tions are less clear. The largest long-term randomized 
controlled study of low-fat diets and weight loss, the 
Women’s Health Initiative, reported in a secondary anal-
ysis that the mean weight loss from baseline in women 
with a body mass index (BMI) >30 over 7.5 years was 
greatest among those who decreased their %E from fat the 
most  [20] . Mean weight loss was significantly related to 
%E from fat, with those who consumed the highest %E 
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 Fig. 1. High-energy diets drive the overconsumption of high-fat 
foods as illustrated in these studies. Ad libitum energy intake by 7 
men consuming diets containing low (20%E), medium (40%E) or 
high (60%E) concentrations of fat with either variable or constant 
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 Yet in a well-controlled intervention study comparing 
the effectiveness of three energy-restricted diets, low fat 
(30%E from fat), Mediterranean (33%E from fat) and 
high fat/low carbohydrate (39%E from fat), on weight loss 
in moderately obese participants, Shai et al.  [21] reported 
that after 2 years those following the low-carbohydrate or 
Mediterranean diets lost significantly more weight (4.7 
and 4.4 kg, respectively) than those on the low-fat diet 
(2.9 kg). After an additional 4 years without intervention, 
participants in the high-fat group regained 4.1 kg, those 
in the low-fat group 2.7 kg and those following the medi-
um-fat Mediterranean diet 1.4 kg (p = 0.004 for all com-
parisons)  [22] . Over the 6-year period, those on the Med-
iterranean diet had a significantly greater weight loss (3.1 
kg) compared with the low-fat (0.6 kg) and high-fat (1.7 
kg) diet groups. Differences in weight loss between the 
low-fat and high-fat/low-carbohydrate groups were not 
significant.
 In a systematic review and meta-analysis of 33 ran-
domized controlled trials and 10 cohort studies on the 
relation between total fat intake and body weight, Hoo-
per et al.  [23] concluded that high-quality evidence sup-
ports the association between lower fat intake and small 
but significant sustained reductions in body weight. 
Greater reductions in total fat and higher baseline fat in-
takes were associated with greater weight loss. The asso-
ciation was less clear in the 10 cohort studies where only 
31% reported a significant positive association between 
fat content and weight gain, while in studies longer than 
1 year, only half showed a significant positive association. 
However, all studies except 1 showed a high risk of bias.
 Data from pragmatic trials of dietary interventions for 
weight loss show the high interindividual variability in 
response, suggesting the outcome may depend on factors 
other than the fat content of the diet. For example, a com-
munity-based open study of participants whose BMI 
ranged from 27 to 40 compared 4 popular weight loss 
programs of variable fat content with a control group who 
maintained their regular diet. After 6 months, all groups 
lost weight compared with the control group, but the 
mean weight loss did not differ among the programs  [24] . 
Likewise, a similar study comparing 4 weight loss diets, 
including the low-fat Ornish diet and high-fat Atkins 
diet, reported that after 1 year, participants in each diet 
group lost modest amounts of weight, but the amount did 
not differ among diets and interindividual variability was 
high  [25] . Increased self-reported dietary adherence was 
associated with greater weight loss irrespective of diet.
 Jebb concluded by noting that any dietary strategy to 
prevent or treat obesity must address total energy intake 
rather than fat content per se and include behavioral 
strategies to maximize adherence. However, since the ul-
timate goal of weight loss among overweight and obese 
individuals is to reduce health risks, especially the burden 
of cardiovascular disease, it is important to consider the 
fatty acid composition of the diet to maximize broader 
health benefits. 
 Fat Quality in Obesity and Insulin Resistance  
 Ulf Risérus, associate professor of clinical nutrition 
and metabolism, Uppsala University, Sweden, discussed 
the involvement of dietary fatty acids in the development 
of obesity, insulin resistance and type 2 diabetes. In insu-
lin resistance and obesity, plasma levels of free fatty acids 
increase because of the impaired ability of the liver, adi-
pose tissue and skeletal muscle to take up and convert the 
fatty acids to glucose or store them as triglycerides. How-
ever, as adipose tissue increases, the release of free fatty 
acids per kilogram adipose tissue may be downregulated, 
so that free fatty acid concentrations in plasma may be in 
the normal range  [26] . Insulin resistance is also associ-
ated with long-term lipid overload, as observed in the ac-
cumulation of lipids outside subcutaneous adipose tissue 
(ectopic fat), such as skeletal muscle, visceral and liver fat. 
This may result from impaired lipid deposition in adipose 
tissue and impaired oxidative capacity  [26] . Thus, dietary 
effects on body weight and total body fat are expected to 
have less favorable metabolic effects unless abdominal 
and ectopic fat are decreased as well.
 Dietary fat quality affects the risk of diabetes, and in-
sulin resistance and sensitivity in healthy, obese and dia-
betic individuals. High serum levels of saturated fatty ac-
ids (SFA) were reported to predict the development of 
MetS  [27] , while the risk of diabetes was inversely associ-
ated with vegetable fat, polyunsaturated fatty acid (PUFA) 
intakes and higher serum levels of ω–6 (n–6) PUFAs  [28, 
29] . However, in a large prospective cohort of women fol-
lowed for 14 years, the risk of type 2 diabetes was not as-
sociated with saturated or monounsaturated fat con-
sumption, but was significantly reduced with higher in-
takes of PUFA  [30] .
 The effects of different types of dietary fatty acids on 
obesity and fat accumulation have not been extensively 
investigated. Controlled feeding studies in animals indi-
cate that in general SFA are more fattening than similar 
intakes of PUFA. For example, in mice fed corn oil (high 
in linoleic acid, the major dietary n–6 PUFA), only 31% 
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in mice fed a beef tallow diet (high palmitic acid, the ma-
jor dietary SFA). Some evidence suggests that diets high 
in SFA increase the risk of obesity  [31] and weight gain 
 [32] and reduce insulin sensitivity  [33] . In a small cross-
over study of obese men, substitution of SFA with mono-
unsaturated fat for 4 weeks was associated with signifi-
cantly lower body weight and fat mass without a change 
in energy or fat intake  [34] . A lifestyle study for the reduc-
tion in high blood pressure reported that a higher intake 
of SFA at 6 months was associated with greater weight at 
18 months, whereas a lower SFA intake predicted lower 
body weight  [32] . It has been shown in several controlled 
feeding studies that palmitic acid results in lower fat oxi-
dation than diets rich in monounsaturated fatty acids 
 [35] . 
 A large trial among obese participants with MetS in 8 
countries reported that reducing SFA intake by increas-
ing monounsaturated fat or ω–3 (n–3) PUFA or carbohy-
drate had no effect on insulin sensitivity when weight was 
stable  [36] . However, a previous multicenter trial indi-
cated a beneficial insulin-sensitizing effect of such a di-
etary fat modification, especially when the total fat con-
tent did not exceed 37%E  [37] . Thus, the interventional 
data on monounsaturated fatty acids and insulin sensitiv-
ity are inconclusive, but no large trials replacing SFA with 
n–6 PUFA have been conducted.
 Data on the effect of increasing PUFA at the expense 
of SFA remain limited and inconsistent. Research in ani-
mals and humans suggest that PUFA are associated with 
improved weight loss in some studies, but not others  [38] . 
In a study of individuals with type 2 diabetes, obesity 
without diabetes or nonobese participants, substitution 
of SFA with PUFA (mainly n–6 PUFA) for 5 weeks on 
each diet in a crossover design resulted in improved insu-
lin sensitivity and reduced abdominal subcutaneous fat 
area compared with the SFA diet  [39] . A comparison of 
conjugated linoleic acid with safflower oil (78% linoleic 
acid) on weight loss in obese women with type 2 diabetes 
reported a lower BMI and total adipose mass after 16 
weeks with conjugated linoleic acid, while higher safflow-
er oil intake was associated with lower trunk adipose mass 
and fasting glucose, with no change in BMI  [40] . These 
findings support the results reported by Summers et al. 
 [39] and suggest a potential reduction of abdominal fat 
and improvement of glucose metabolism by n–6 PUFA 
in obese diabetic individuals.
 Swedish investigators compared the effects of isocalo-
ric diets rich in either PUFA (mainly n–6 PUFA) or SFA 
on liver fat and metabolic parameters in participants with 
abdominal obesity, 15% of whom had type 2 diabetes 
 [41] . Participants consuming foods high in n–6 PUFA 
experienced a significant reduction in liver fat measured 
by magnetic resonance imaging, which was inversely re-
lated to the increased serum linoleic acid levels. Com-
pared with the PUFA diet, those on the SFA-rich diet
exhibited increased liver fat. In addition, PUFA signifi-
cantly reduced the visceral fat/subcutaneous fat ratio 
compared with the SFA diet. Despite weight-stable condi-
tions, the PUFA-rich diet was associated with moderate 
improvements in blood lipids and fasting insulin, where-
as the SFA diet was not. This is the first study to demon-
strate a favorable effect of PUFA-rich foods on ectopic fat 
content in humans, independent of weight change.
 In a recent study of overfeeding normal-weight indi-
viduals with foods high in SFA or n–6 PUFA for 7 weeks, 
those fed the SFA-rich foods had markedly increased liv-
er fat and a 2-fold larger increase in visceral fat compared 
with the PUFA group ( fig. 2 )  [42] . Those consuming the 
PUFA-rich foods had a nearly 3-fold larger increase in 
lean tissue compared with the SFA group. The investiga-
tors concluded that in healthy humans overeating SFA-
rich foods promotes hepatic and visceral fat storage, 
whereas excess energy from n–6 PUFA was associated 
with increased lean tissue. These findings are consistent 
with the observations reported in individuals with ab-
dominal obesity  [41] . 
 n–3 PUFA may have different effects from linoleic 
acid. Most research has focused on the long-chain (LC) 
n–3 PUFA, primarily eicosapentaenoic acid and docosa-
hexaenoic acid found mainly in fish and shellfish. Rodent 
studies have shown that fish oil or n–3 LC-PUFA can re-
duce diet-induced obesity  [43] , have a hypolipidemic ef-
fect on the liver  [44] , increase fatty acid oxidation in adi-
pose tissue  [45] , inhibit fat cell proliferation  [46] , limit fat 
cell hypertrophy and hyperplasia  [47] , and stimulate mi-
tochondrial biogenesis and β-oxidation in white adipose 
tissue  [48] . Thus, an extensive literature of animal studies 
supports the anti-obesity effects of n–3 LC-PUFA.
 Studies on the effects of n–3 PUFA in humans are 
scarce  [49] . Data from epidemiological studies are incon-
sistent, but several large studies reported an inverse asso-
ciation between fish consumption or n–3 LC-PUFA in-
takes and BMI or abdominal obesity  [50, 51] . In severely 
obese women following a very-low-calorie diet, the addi-
tion of 2.8 g/day of n–3 LC-PUFA was associated with a 
significantly greater loss in BMI and hip circumference 
compared with unsupplemented participants  [52] . How-
ever, the addition of supplemental n–3 LC-PUFA to a 24-
week diet and exercise program provided no additional 
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als  [53] . In contrast, the addition of a daily fish meal to a 
weight loss diet was more effective than the weight loss 
diet alone in achieving weight loss over 16 weeks  [54] . 
Fish consumption was not associated with 5- to 10-year 
weight gain in a large prospective cohort study  [55] . In a 
controlled 16-week study in overweight and moderately 
obese healthy adults, increasing the dietary content of 
n–3 PUFA to 3.6%E mainly from fish oil had no effect on 
body weight or fat mass  [56] . A recent review reached a 
similar conclusion  [57] . Thus, fish or n–3 PUFA intakes 
may have little effect on body weight or weight gain.
 Suggestive data, although limited, indicate that dietary 
fat quality may affect the development of adipose tissue 
accumulation and distribution. The effect of dietary fat 
quality in modulating ectopic fat is of clinical interest, as 
liver fat is closely linked to type 2 diabetes. As knowledge 
grows, it may be possible to compose optimal diets that 
minimize abdominal and ectopic fat accumulation, there-
by helping to prevent obesity and its related metabolic 
disorders. 
 Early Lipid Nutrition and Later Risk of MetS 
 Recognizing the rising tide of obesity and type 2 dia-
betes, Prof. Berthold Koletzko, University of Munich 
Medical Center, Munich, Germany, emphasized the im-
portance of early intervention to prevent obesity. Halt-
ing the epidemic of overweight and obesity is urgent be-
cause of the many adverse health conditions linked to 
obesity, the extension of the disorder into early child-
hood, and the growing prevalence of obesity in lower-
income countries  [58] . In the US, more than 35% of 
adults and 17% of children and adolescents were obese 
in 2009–2010  [59] .
 Efforts to better understand the etiology of obesity be-
yond overeating and physical inactivity call attention to 
events in fetal and early life. Studies on early program-
ming during fetal and postnatal life suggest interventions 
with the potential to deter obesity  [60] . So compelling is 
the problem and the importance of early nutrition that a 











































































 Fig. 2. Relative changes in liver fat (%), vis-
ceral adipose tissue (ratio of visceral adi-
pose tissue/total adipose tissue – visceral 
adipose tissue), total body fat and lean tis-
sue (liters) by MRI during 7 weeks of over-
eating SFA or PUFA. Relative changes are 
calculated for each individual as a change 
during the intervention/baseline measure-
ment. Boxes represent medians and inter-
quartile ranges (IQR), whiskers represent 
the most extreme value besides outliers, 
circles represent outliers (>1.5 IQRs out-
side IQR). p values represent changes from 
week 7 to week 0 (between-group t test or 
Wilcoxon test) [reproduced with permis-
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early nutrition on later health has been initiated, which 
was funded by the European Union  [61] .
 Three hypotheses for early developmental program-
ming for obesity have been proposed: (1) ‘fetal overnutri-
tion’ suggests that excess exposure to fuels, as occurs in 
gestational diabetes, causes changes that lead to obesity 
 [62] ; (2) accelerated postnatal weight gain proposes an 
association between rapid weight gain in infancy and an 
increased risk of later obesity  [63] , and (3) mismatch be-
tween fetal undernutrition and postnatal overnutrition 
suggests that experiencing suboptimal fetal nutrition and 
an obesogenic childhood environment predisposes to 
obesity. A well-known example of the latter is the survi-
vors of the Dutch famine in the winter of 1944–1945, 
many of whom were born small for gestational age and 
later experienced increased incidence of obesity, diabetes 
and other chronic diseases  [64] .
 Excessive perinatal fuel supply of glucose or fat pro-
motes higher insulin and greater fetal fat deposition dur-
ing the last trimester  [65] . Women with gestational dia-
betes or mild glucose intolerance and obesity have at least 
a 3-fold greater risk of having an infant above the 90th 
percentile in body weight and percent body fat  [66, 67] . 
Substantial data indicate that maternal obesity predispos-
es the infant to overweight, obesity and MetS  [68–70] . 
 Rapid weight gain in infancy has consistently been 
associated with a significantly higher risk of overweight 
or obesity in preschool and young children  [71, 72] 
( fig. 3 ), as recently reviewed  [88, 89] . More rapid child-
hood growth is also associated with a higher risk of obe-
sity in adult life  [90] , insulin resistance  [91] , compo-
nents of MetS  [92] and a more atherogenic lipid profile 
in adolescence  [93] . A high-protein infant formula also 
contributes to greater BMI and insulin-like growth fac-
tor-1 in infants at 6 months through 2 years of age com-
pared with breastfed infants or those fed lower protein 
formula  [94] .
 There appears to be a transgenerational effect of obe-
sity, with the strength of the association between parental 
and childhood obesity increasing between generations 
 [95] , as shown in  table 1 . Few studies have examined this 
question, but a study on the birth information of mothers 
and their offspring from the Swedish Medical Birth Reg-
ister reported that mothers born large for gestational age 
had increased risks of overweight and obesity and were at 
an increased risk of having a large-for-gestational-age in-
fant as their BMI increased  [96] . Interestingly, mothers 
born small for gestational age had the highest risk – 13 
times greater – of having large-for-gestational-age off-
spring. Similarly, US data reported that the strongest per-
sistence of BMI across generations occurred among those 
with higher BMI levels  [97] .
 The final question discussed by Koletzko was whether 
the relative proportions of dietary n–6 and n–3 PUFA 
contribute to obesity and MetS risk. In many western 
countries, the increased consumption of n–6 PUFA, 
mainly from linoleic-acid-rich vegetable oils, and re-
 Table 1.  Odds ratios [OR (±95% CI)] for child overweight or obe-
sity according to maternal and infant predictive factors [adapted 
from 95]
Predictive factor Adjusted OR (95% CI) 
for child overweight or 
obesity at age 7 years
Adjusted OR (95% CI) 
for second-generation 
child overweight or 
obesity at age 4 – 9 years
Maternal over-
weight 1.45 (1.19 – 1.75) 1.69 (1.00 – 2.85)
Maternal obesity 2.29 (1.76 – 2.97) 3.20 (1.85 – 5.54)























 Fig. 3. Risk (odds ratios) of obesity in childhood, adolescence and 
adulthood with rapid weight gain in infancy or the first 2 years of 
life based on data from 16 studies  [89] and adapted from Adair 
 [123] . The adjusted risk of obesity across all ages exceeded 1. Obe-
sity was defined as BMI >95th percentile and rapid weight gain as 
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duced intakes of n–3 PUFA parallel the sharp increase in 
the prevalence of obesity and type 2 diabetes  [98–100] . 
Although the number of adipocytes is established in 
childhood  [101] , the greatest proliferation and differen-
tiation of adipocyte precursor cells occurs during the 1st 
year of life and at prepuberty  [102] . In animals, diets high 
in n–6 PUFA increase the differentiation and prolifera-
tion of preadipocytes, which increases the number of ad-
ipocytes and the accumulation of fat  [103, 104] . Animals 
fed 35% fat diets containing either 1 or 8%E from linoleic 
acid or 8% linoleic acid plus 1% n–3 LC-PUFA exhibited 
increased obesity on the 8% linoleic acid diet, but had 
equivalent fat tissue when fed either level of linoleic acid 
supplemented with n–3 LC-PUFA  [105] . Similar findings 
were reported in mice fed diets rich in linoleic acid or lin-
oleic acid plus α-linolenic acid, where fat mass and adipo-
cyte size at 8 weeks were higher in the linoleic acid-fed 
animals compared with those fed both n–6 and n–3 PUFA 
 [106] . Little robust animal data exist on the effects of in-
creased perinatal PUFA exposure on body fat mass in the 
offspring.
 In humans, observational studies suggest that high 
maternal plasma n–6 PUFA at 34 weeks of gestation pre-
dicted offspring fat mass at 4 and 6 years of age  [107] . A 
study of maternal PUFA intake and status during preg-
nancy and child adiposity at age 3 years reported that a 
higher ratio of n–6:n–3 PUFA in the maternal diet, plas-
ma and cord blood was associated with higher child adi-
posity  [108] . In the same study, higher maternal docosa-
hexaenoic and eicosapentaenoic acid intakes were associ-
ated with a lower skinfold thickness measures at age 3. 
Fish oil supplementation in pregnancy was unrelated to 
adolescent obesity at 19 years of age  [109] . A recent inter-
vention study examined the reduction in the maternal in-
take of n–6:n–3 LC-PUFA during pregnancy and the first 
4 months of lactation  [110] . Participants were counseled 
to reduce their intake of arachidonic acid and consume a 
daily supplement providing 1,020 mg docosahexaenoic 
acid, 180 mg eicosapentaenoic acid and 9 mg of vitamin 
E. The control group was counseled to eat a healthy diet. 
Up to 12 months of age, there were no statistically sig-
nificant differences in the fat mass or skinfold thickness 
measurements in the offspring of the intervention and 
control groups. 
 Overall, few randomized controlled trials have inves-
tigated different intakes of n–6 and n–3 PUFA in preg-
nancy and subsequent offspring obesity. Two reviews
of human studies on child adiposity and maternal LC-
PUFA intake reported inconsistent findings on PUFA in-
takes and offspring BMI or obesity  [111, 112] . Thus, the 
quantity and quality of available data in humans permit 
no conclusions about LC-PUFA and childhood obesity.
 Koletzko concluded that pre- and postnatal overfeed-
ing increases the risk for obesity and associated disorders 
and that it is biologically plausible that diets high in n–6 
PUFA or high in n–6:n–3 PUFA could have potential ad-
verse effects on pre- and postnatal obesity. He noted that 
n–3 LC-PUFA may have potential benefits on insulin 
sensitivity and associated outcomes in overweight chil-
dren and emphasized that high SFA diets should be 
avoided, but at this time evidence for a causal relationship 
is not available. Currently, there is no basis to change cur-
rent recommendations on dietary fat quality in pregnan-
cy, lactation and infancy.
 Do High- or Low-Fat Diets Counteract MetS? 
 Weight loss is the first line of defense in MetS, af-
firmed Jennifer Fleming, Pennsylvania State University, 
University Park, Pa., USA. Weight reduction strategies 
have focused primarily on the effectiveness of reduced-
carbohydrate (<50% total E) versus low-fat (<30%E) di-
ets. Although both diets are associated with weight loss 
 [113] , intervention studies with reduced dietary fat have 
not consistently achieved positive long-term results on 
body weight or MetS criteria despite short-term weight 
loss. In contrast, reduced-carbohydrate diets have dem-
onstrated improved blood lipid profiles, reduced blood 
pressure, plasma glucose and visceral adiposity, and 
have been associated with long-term weight loss (i.e. 2 
years)  [21] . A recent review by Schwingshackl and Hoff-
mann  [114] supports these findings. However, Sacks et 
al.  [115] reported no differences in weight loss after 2 
years between those following low-fat (20%E), high-car-
bohydrate (55–65%E) versus high-fat (40%E), lower-
carbohydrate (35–45%E) diets with varying protein 
content. However, the macronutrient targets of the diets 
were not met. Notably, the greatest weight loss occurred 
among those with the highest dietary compliance. This 
observation was reinforced by results from the A to Z 
weight loss study  [116] . Collectively, research shows 
that beyond focusing on the macronutrient profile, it is 
important to identify a dietary pattern that can be fol-
lowed long-term.
 Emerging evidence suggests that certain dietary pat-
terns may be more effective for weight loss in some over-
weight or obese groups depending on their metabolic sta-
tus, particularly their insulin sensitivity. Risk factors for 
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tially among obese individuals, with insulin resistance 
characterizing those with the greatest risk  [117] .
 A study comparing two reduced energy diets, either 
high in carbohydrates (60%E) and low in fat (20%E) or 
low in carbohydrates (40%E) and high in fat (40%E), in 
obese women who were either insulin sensitive or insulin 
resistant found that the insulin-sensitive women con-
suming the high-carbohydrate diet lost significantly 
more weight than insulin-sensitive women consuming 
the low-carbohydrate, high-fat diet (13.5 vs. 6.8% of ini-
tial body weight, respectively). In contrast, insulin-resis-
tant women lost significantly more weight on the low-
carbohydrate diet compared with the insulin-resistant 
women consuming the high-carbohydrate diet (13.4 vs. 
8.5% of initial body weight, respectively)  [118] . The in-
vestigators concluded that the state of insulin sensitivity 
determined the effectiveness of the macronutrient distri-
bution in the weight loss diets consumed by these obese 
women.
 In an 18-month study comparing a low-glycemic-load 
diet (40% carbohydrate and 35% fat) with a low-fat diet 
(55% carbohydrate and 20% fat) in obese young adults, 
participants with an insulin concentration above the me-
dian 30 min after an oral glucose dose consuming the low 
glycemic load diet experienced greater weight loss (–5.8 
vs. –1.2 kg; p = 0.004) and decreased percent body fat 
(–2.6 vs. –0.9%; p = 0.03) than those consuming the low-
fat diet  [119] . The authors suggested that reducing the 
glycemic load might be especially important for achieving 
weight loss in individuals with high insulin secretion. 
Consistent with these findings was the observation that 
adherence to either a low-fat ( ≤ 10%E) or low-carbohy-
drate ( ≤ 50 g/day) diet among obese women was related 
to the insulin resistance status only for those on the low-
fat diet  [105] . Insulin-resistant participants were less like-
ly to adhere to and lose weight on a low-fat diet compared 
to insulin-sensitive participants. Further, insulin-resis-
tant women who consumed the low-carbohydrate diet 
experienced a significant reduction in their fasting insu-
lin level compared with participants consuming the low-
fat diet (–5.8 vs. –0.2 μIU/ml, p < 0.0001) or with insulin-
sensitive women on the same diet (–5.8 vs. 0.1 μIU/ml,
p < 0.001)  [120] .
 When designing low-carbohydrate diets, the question 
arises whether protein or unsaturated fat should replace 
the carbohydrate. In a study comparing carbohydrate re-
placement with protein or monounsaturated fat in the 
diets of overweight and obese volunteers with elevated 
fasting insulin levels (>12 mU/l), investigators reported 
that weight loss (approx. 10 kg), improvements in insulin 
resistance and changes in cardiovascular risk factors did 
not differ between the groups after 12 weeks of energy 
restriction  [121] . Fleming cautioned that the long-term 
effects of high-protein diets have not been extensively in-
vestigated, may be high in SFA and/or low in nutrient 
density, may be expensive or impractical, and are associ-
ated with declining adherence over time. Whether the re-
placement fat should be predominately monounsaturat-
ed or PUFA is unclear, as both types of fat are associated 
with improved lipid profile, increased insulin sensitivity, 
and lower blood pressure and abdominal fat when com-
pared with dietary carbohydrate.
 Fleming shared findings from a meta-analysis of 50 
studies of the Mediterranean diet in patients with MetS, 
which reported significant associations between the diet 
and reduced waist circumference, increased HDL-choles-
terol and lower triglyceride levels, lower systolic and dia-
stolic blood pressures, and reduced glucose levels and in-
sulin resistance  [122] . These studies suggest that success-
ful management of MetS is dependent on dietary patterns 
that have a moderate macronutrient composition and are 
nutrient dense.
 The symposium participants agreed that preventing 
weight gain and tackling weight loss are key strategies for 
reducing MetS. Both low-fat and low-carbohydrate diets 
can lead to weight loss, but adherence to the dietary strat-
egy trumps the macronutrient distribution. Avoiding 
high SFA diets contributes to a reduction in health risks 
for obese, MetS and diabetic patients. Healthy maternal 
weight at conception and in pregnancy is more important 
than weight gain during pregnancy in affecting the risk of 
obesity in the offspring. The effects of different PUFA dis-
tributions on MetS and weight loss await clarification.
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